H. Lundbeck A/S Newsletter
-
The Escalator: Regeneron, Lundbeck, Amgen and more
29 Jan 2026 12:31 GMT
… joined Rosemont Pharmaceuticals as CEO.
Lundbeck named Richard Kim as SVP …
-
Lundbeck 'not willing to compromise' on M&A strategy after missed Avadel attempt: exec
22 Jan 2026 17:10 GMT
… partnered atypical antipsychotic is currently Lundbeck’s top-selling product, … corporate, portfolio and product strategy
(Lundbeck)
Gibbs described “programmatic business development … EVP and head of Lundbeck U.S.
(Lundbeck)
Following the separation, Rexulti …
-
Lundbeck price target lowered to DKK 50 from DKK 53 at Barclays
07 Jan 2026 01:06 GMT
Barclays lowered the firm’s price target on Lundbeck (HLBBF) to DKK 50 from DKK 53 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
-
Rising Stars: Lundbeck’s Andrew Willett is leaving the world a better place through pharma comms
17 Dec 2025 12:05 GMT
… in your role?
Andrew Willett
(Lundbeck)
Andrew Willett: I didn’t … learned about this opportunity at Lundbeck. I’ll admit, it … really was Lundbeck’s purpose that inspired me … is still happening today.
[At Lundbeck,] one that I found especially …
-
Zuellig Pharma expands partnership with Lundbeck for commercialisation of neuro-psychiatric health solutions in Asia
16 Dec 2025 14:53 GMT
Zuellig Pharma expands partnership with Lundbeck for commercialisation of neuro-psychiatric … | News
Zuellig Pharma will commercialise Lundbeck's portfolio of products … its existing distribution agreement with Lundbeck, under which Zuellig Pharma has …
-
Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
06 Dec 2025 21:42 GMT
… #47; — H. Lundbeck A/S (Lundbeck) today announced results from … presentations at AES 2025, Lundbeck demonstrates the breadth of its … 01
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical … #47;news-releases/lundbeck-announces-positive-phase-2-long …
-
Lundbeck To Present Comprehensive New Bexicaserin Dataset In Patients With Rare Childhood-Onset Epilepsies, At American Epilepsy Society (AES) Annual Meeting
02 Dec 2025 10:09 GMT
… Eight presentations at AES highlight Lundbeck's dedication to … Research & Development at Lundbeck. "The data for …
During the AES congress, Lundbeck will also showcase two-year … have not been established.
Lundbeck's scientific presentations …
-
Lundbeck Ends Bidding War for Avadel, After Alkermes’ Up-to-$2.37B Offer
02 Dec 2025 05:16 GMT
… value creation,” Lundbeck said in a statement. “Lundbeck’s disciplined … psychiatry. Within neurology, Lundbeck’s sub-focus areas … sleep-wake disorders
“Lundbeck continues to assess opportunities … the company further stated.
Lundbeck finished the third quarter …
-
Lundbeck bows out of bidding war for Avadel
27 Nov 2025 20:57 GMT
… ."
It added: "Lundbeck's disciplined approach requires … review, Avadel concluded that Lundbeck's offer was … achieved."
"While Lundbeck is discontinuing this specific process … fully intact," said Lundbeck, which added that it …
-
Lundbeck backs out of bidding war for sleep disorder biotech Avadel
26 Nov 2025 23:05 GMT
About
© 1995-2026